Skip to main content

Table 2 Each effectiveness of Iron supplementation or Iron supplementation with Ninjin’yoeito for treating perioperative anemia, fatigue and anxiety

From: Safety and efficacy of Ninjin’yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, single-center, randomized phase-II trial

 

Iron supplementation group (N = 15)

NYT group (N = 15)

Pre-treatment

Post-treatment

P value

Pre-treatment

Post-treatment

P value

Hemoglobin-g/dL

9.9 ± 0.8

11.9 ± 1.6

0.0005

9.8 ± 1.0

12.0 ± 1.0

0.0001

Hematocrit-%

32.3 ± 2.1

37.1 ± 4.3

0.001

32.7 ± 2.1

38.2 ± 3.3

0.0002

Median serum iron level (IQR)-µg/dL

27 (14, 84) $

125 (88, 214)~

0.055

32 (15, 146) #

100 (81, 205) |

0.38

Median ferritin (IQR)-ng/mL

10 (5, 22) $

26 (16, 31) ~

0.063

4 (3, 10) #

19 (10, 26) |

0.0078

CFS

 Physical

5.9 ± 5.1

4.1 ± 4.1

0.23

7.1 ± 5.4

2.5 ± 2.4

0.0005

 Affective

6.5 ± 3.0

6.5 ± 2.5

0.96

7.9 ± 4.1

4.9 ± 3.4

0.025

 Cognitive

3.5 ± 3.7

2.0 ± 2.3

0.094

2.8 ± 2.8

0.7 ± 1.0

0.002

 Total

15.9 ± 9.3

12.5 ± 6.5

0.1

17.9 ± 10.2

8.1 ± 5.2

0.0004

Median VAS-A (IQR)-mm

50 (8, 65)

32 (13, 57)

0.2

56 (50, 70)

23 (6, 48)

0.0009

Median PSQI (IQR)

4 (3, 5)

4 (3, 6)

1

5 (3, 7)

4 (3, 5)

0.15

  1. Plus-minus values are mean ± standard deviation; analyzed with Wilcoxon signed rank test
  2. CFS cancer fatigue scale, VAS-A visual analogue scale for anxiety, PSQI Pittsburgh sleep quality index, IQR interquartile range
  3. $, N = 9; #, N = 8; ~ , N = 13; |, N = 11